Evidence map›Paper›PMID 24552491›Full record

ArticleBMC cancer2014

Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France.

Florence Menegaux, Antoinette Anger, Hasina Randrianasolo, Claire Mulot, Pierre Laurent-Puig, François Iborra, Jean-Pierre Bringer, Benoit Leizour, Rodolphe Thuret, Pierre-Jean Lamy and 3 more

Abstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP).Journal of occupational medicine and toxicology (London, England) · 2022
    Article
  7. Article
  8. Observational
  9. Article
  10. Night work and prostate cancer risk: results from the EPICAP Study.Occupational and environmental medicine · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Florence MenegauxINSERM U1018, Center for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Team, 16av, Paul Vaillant Couturier, 94807 Villejuif Cédex, France. florence.menegaux@inserm.fr.
Antoinette Anger
Hasina Randrianasolo
Claire Mulot
Pierre Laurent-Puig
François Iborra
Jean-Pierre Bringer
Benoit Leizour
Rodolphe Thuret
Pierre-Jean Lamy
Xavier Rébillard
Brigitte Trétarre
EPICAP Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is the most common cancer in male in most Western countries, including France. Despite a significant morbidity and mortality to a lesser extent, the etiology of prostate cancer remains largely unknown. Indeed, the only well-established risk factors to date are age, ethnicity and a family history of prostate cancer. We present, here, the rationale and design of the EPIdemiological study of Prostate CAncer (EPICAP), a population-based case-control study specifically designed to investigate the role of environmental and genetic factors in prostate cancer. The EPICAP study will particularly focused on the role of circadian disruption, chronic inflammation, hormonal and metabolic factors in the occurrence of prostate cancer. METHODS/

designEPICAP is a population-based case-control study conducted in the département of Hérault in France. Eligible cases are all cases of prostate cancers newly diagnosed in 2012-2013 in men less than 75 years old and residing in the département of Hérault at the time of diagnosis. Controls are men of the same age as the cases and living in the département of Hérault, recruited in the general population.The sample will include a total of 1000 incident cases of prostate cancer and 1000 population-based controls over a 3-year period (2012-2014).The cases and controls are face-to-face interviewed using a standardized computed assisted questionnaire. The questions focus primarily on usual socio-demographic characteristics, personal and family medical history, lifestyle, leisure activities, residential and occupational history. Anthropometric measures and biological samples are also collected for cases and controls. DISCUSSION: The EPICAP study aims to answer key questions in prostate cancer etiology: (1) role of circadian disruption through the study of working hours, chronotype and duration/quality of sleep, (2) role of chronic inflammation and anti-inflammatory drugs, (3) role of hormonal and metabolic factors through a detailed questionnaire, (4) role of individual genetic susceptibility of genes involved in biological pathways of interest. The EPICAP study will also allow us to study prognostic factors and tumor aggressiveness.Taken together, the EPICAP study will provide a comprehensive framework to go further in the understanding of prostate cancer occurrence and its prognosis.

Indexed as

Population SurveillanceAgedCase-Control StudiesFranceHumansMaleMiddle AgedPilot ProjectsProstatic NeoplasmsRegistriesRisk FactorsSurveys and Questionnaires

Identifiers

PMID24552491
PMCPMC3936778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.